Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Anemia, Refractory, with Excess of Blasts 115Myelodysplastic Syndromes 107Leukemia 98Leukemia, Myeloid, Acute 92Anemia 70Leukemia, Myelomonocytic, Chronic 68Precursor Cell Lymphoblastic Leukemia-Lymphoma 67Myeloproliferative Disorders 55Leukemia, Lymphocytic, Chronic, B-Cell 52Multiple Myeloma 48Anemia, Refractory 48Thrombocytopenia 45Lymphoma 43Lymphoma, Non-Hodgkin 42Neoplasms 40Hodgkin Disease 39Primary Myelofibrosis 36Leukemia, Myeloid, Chronic-Phase 36Congenital Abnormalities 34Anemia, Aplastic 34Myelodysplastic-Myeloproliferative Diseases 33Leukemia, Myelogenous, Chronic, BCR-ABL Positive 33Leukemia, Myeloid, Accelerated Phase 32Lymphoma, Follicular 29Blast Crisis 27Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 26Burkitt Lymphoma 25Lymphoma, Mantle-Cell 24Neoplasms, Plasma Cell 23Lymphoma, B-Cell, Marginal Zone 23

Interventions

Fentanyl 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Breakthrough Pain × Classical hematology × Clear all
NCT00236041 2014-05-09

Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
38 enrolled
Classical hematology

Agnosia, Anemia, Sickle Cell, Burns, Neoplasms, Breakthrough Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡